Report Publication Announcement • Apr 7, 2022
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 6315H
Indivior PLC
07 April 2022
Indivior to Announce Q1 2022 Results and Host Webcast on April 28th
Slough, UK, and Richmond, VA, April 7, 2022 - Indivior PLC (LON: INDV) today announced that it will release its Q1 2022 results on April 28th at 12:00 GMT (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.
Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on April 28th.
Access to the Live Webcast Presentation
The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins.
The webcast link is https://edge.media-server.com/mmc/p/ogy6nn93.
Participants may access the presentation telephonically:
· US participants 1-646-741-3167
· International participants +44 (0) 2071-928338
Please reference confirmation ID 6687840. A replay of the presentation will be available at www.indivior.com.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or [email protected]
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or [email protected]
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORBKOBBFBKKDQK
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.